Display options
Cite
Ballantyne CM, Manku MS, Bays HE, et al. Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study. Cardiol Ther. 2019;8(1):79-90doi: 10.1007/s40119-019-0131-8.
Ballantyne, C. M., Manku, M. S., Bays, H. E., Philip, S., Granowitz, C., Doyle, R. T., & Juliano, R. A. (2019). Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study. Cardiology and therapy, 8(1), 79-90. https://doi.org/10.1007/s40119-019-0131-8
Ballantyne, Christie M, et al. "Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study." Cardiology and therapy vol. 8,1 (2019): 79-90. doi: https://doi.org/10.1007/s40119-019-0131-8
Ballantyne CM, Manku MS, Bays HE, Philip S, Granowitz C, Doyle RT, Juliano RA. Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study. Cardiol Ther. 2019 Jun;8(1):79-90. doi: 10.1007/s40119-019-0131-8. Epub 2019 Feb 20. PMID: 30788718; PMCID: PMC6525216.
Copy Download .nbib Format: NLM
Share it on

Cardiol Ther. 2019 Jun;8(1):79-90. doi: 10.1007/s40119-019-0131-8. Epub 2019 Feb 20.

Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study.

Cardiology and therapy

Christie M Ballantyne, Mehar S Manku, Harold E Bays, Sephy Philip, Craig Granowitz, Ralph T Doyle, Rebecca A Juliano

Affiliations

  1. Department of Medicine, Baylor College of Medicine and the Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, USA. [email protected].
  2. Amarin Pharma Inc, Bedminster, NJ, USA.
  3. Clinical Research, Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA.
  4. Medical Affairs, Amarin Pharma Inc, Bedminster, NJ, USA.
  5. Research and Development, Amarin Pharma Inc, Bedminster, NJ, USA.

PMID: 30788718 PMCID: PMC6525216 DOI: 10.1007/s40119-019-0131-8

Abstract

INTRODUCTION: Fatty acid content in plasma and red blood cells (RBCs) may provide insight into potential physiologic benefits of omega-3 fatty acids. Icosapent ethyl is a pure prescription form of eicosapentaenoic acid (EPA) ethyl ester approved by the US Food and Drug Administration at a dose of 4 g/day as an adjunct to diet to reduce triglyceride levels in adults with severe (≥ 500 mg/dl) hypertriglyceridemia.

METHODS: This was a prespecified exploratory subset analysis of the ANCHOR study, which randomized 702 statin-treated patients at increased cardiovascular risk with triglycerides 200-499 mg/dl and controlled low-density lipoprotein cholesterol (40-99 mg/dl). This analysis examined effects of icosapent ethyl 4 g/day versus placebo on fatty acid levels in plasma and RBCs using a gas chromatograph assay method with flame ionization detector.

RESULTS: In plasma, treatment with icosapent ethyl 4 g/day resulted in significant increases versus placebo in the mean concentrations of EPA (+ 635%; P < 0.0001) and its metabolite, docosapentaenoic acid n-3 (+ 143%; P < 0.0001) with no significant change in docosahexaenoic acid. Treatment with icosapent ethyl 4 g/day versus placebo also resulted in significant decreases in the omega-6 fatty acids linoleic acid (- 25%) and arachidonic acid (AA; - 31%), as well as the AA/EPA ratio (- 91%). Icosapent ethyl 4 g/day also decreased the omega-9 fatty acid oleic acid (- 29%) and the saturated fatty acids palmitic acid (- 23%) and stearic acid (- 16%) (all P < 0.0001). Results were similar for RBCs.

CONCLUSIONS: Icosapent ethyl 4 g/day significantly increased EPA and produced other potentially beneficial shifts in fatty acids in plasma and RBCs versus placebo.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier, NCT01047501 FUNDING: Amarin Pharma Inc. Plain language summary available for this article.

Keywords: Arachidonic acid; Eicosapentaenoic acid; Fatty acids; Hypertriglyceridemia; Icosapent ethyl; Omega-3 fatty acids; Omega-6 fatty acids

References

  1. Atherosclerosis. 1999 Apr;143(2):285-97 - PubMed
  2. Int J Clin Lab Res. 1999;29(1):22-5 - PubMed
  3. Am J Clin Nutr. 2000 Jan;71(1 Suppl):343S-8S - PubMed
  4. Prev Med. 2004 Jul;39(1):212-20 - PubMed
  5. Circulation. 2004 Sep 21;110(12):1645-9 - PubMed
  6. Am J Clin Nutr. 2006 Jun;83(6 Suppl):1505S-1519S - PubMed
  7. Cardiovasc Res. 2007 Jan 15;73(2):310-5 - PubMed
  8. Lancet. 2007 Mar 31;369(9567):1090-8 - PubMed
  9. Clin Biochem. 2010 Feb;43(3):338-40 - PubMed
  10. J Atheroscler Thromb. 2011;18(2):99-107 - PubMed
  11. Am J Cardiol. 2011 Sep 1;108(5):682-90 - PubMed
  12. Ann Intern Med. 2011 Aug 2;155(3):160-70 - PubMed
  13. J Am Coll Cardiol. 2011 Nov 8;58(20):2047-67 - PubMed
  14. J Clin Lipidol. 2012 Jan-Feb;6(1):5-18 - PubMed
  15. Am J Cardiol. 2012 Oct 1;110(7):984-92 - PubMed
  16. Int J Cardiol. 2013 Sep 20;168(1):53-9 - PubMed
  17. J Clin Lipidol. 2012 Nov-Dec;6(6):565-72 - PubMed
  18. Am J Cardiovasc Drugs. 2013 Feb;13(1):37-46 - PubMed
  19. Prostaglandins Leukot Essent Fatty Acids. 2013 Sep;89(4):195-201 - PubMed
  20. J Atheroscler Thromb. 2013;20(12):861-77 - PubMed
  21. Atherosclerosis. 2015 Sep;242(1):357-66 - PubMed
  22. Manag Care. 2016 Jan;25(1):46-52 - PubMed
  23. J Clin Lipidol. 2016 May-Jun;10(3):635-645.e1 - PubMed
  24. Prostaglandins Other Lipid Mediat. 2016 Sep;125:57-64 - PubMed
  25. Atherosclerosis. 2016 Oct;253:81-87 - PubMed
  26. Clin Cardiol. 1986 Sep;9(9):413-6 - PubMed
  27. N Engl J Med. 2019 Jan 3;380(1):91-93 - PubMed
  28. N Engl J Med. 2019 Jan 3;380(1):11-22 - PubMed
  29. JAMA. 1995 Nov 1;274(17):1363-7 - PubMed
  30. Am J Clin Nutr. 1997 Sep;66(3):649-59 - PubMed
  31. J Lipid Res. 1997 Oct;38(10):2012-22 - PubMed
  32. J Cardiovasc Risk. 1997 Oct-Dec;4(5-6):385-91 - PubMed

Publication Types

Grant support